<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431561</url>
  </required_header>
  <id_info>
    <org_study_id>AP 12009-G004</org_study_id>
    <nct_id>NCT00431561</nct_id>
  </id_info>
  <brief_title>Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma</brief_title>
  <official_title>Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isarna Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isarna Therapeutics GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP
      12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult
      patients with confirmed recurrent high-grade glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of two doses of AP 12009 and
      standard chemotherapy in adult patients with recurrent high-grade glioma (anaplastic
      astrocytoma [AA], WHO grade III; or glioblastoma [GBM], WHO grade IV). AP 12009 is a
      phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human transforming
      growth factor-beta2 (TGF-beta2). The growth factor TGF-beta plays a key role in malignant
      progression of various tumors by inducing proliferation, invasion, metastasis, angiogenesis
      and escape from immunosurveillance. It has been shown that in a number of tumor types the
      degree of TGF-beta production strongly correlates with tumor grade and stage. In patients
      with high-grade glioma, the TGF-beta2 overexpression is associated with disease stage,
      clinical prognosis and the immunodeficient state of the patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>overall</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>six- and twelve-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>at 3, 8, 10, and 12 months (and during the prolonged follow-up period in six-monthly intervals, if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>six-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best of all response rates assessed by survival status and variation of tumor size on brain MRI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life and Karnofsky Performance Status (KPS)</measure>
    <time_frame>at 3, 8, 10, and 12 months (and during the prolonged follow-up period in six-monthly intervals, if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best of all response rates</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <arm_group>
    <arm_group_label>AP 12009 10 µM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AP 12009 80 µM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP 12009 10 µM</intervention_name>
    <description>10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks</description>
    <arm_group_label>AP 12009 10 µM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP 12009 80 µM</intervention_name>
    <description>80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks</description>
    <arm_group_label>AP 12009 80 µM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide or PCV</intervention_name>
    <description>temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
    <other_name>TMZ</other_name>
    <other_name>lomustine</other_name>
    <other_name>Cecenu</other_name>
    <other_name>CeeNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug delivery system for administration of AP 12009</intervention_name>
    <description>Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.</description>
    <arm_group_label>AP 12009 10 µM</arm_group_label>
    <arm_group_label>AP 12009 80 µM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placement of Drug Delivery System</intervention_name>
    <description>Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.</description>
    <arm_group_label>AP 12009 10 µM</arm_group_label>
    <arm_group_label>AP 12009 80 µM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed diagnosis of recurrent or refractory high-grade glioma
             (anaplastic astrocytoma, WHO grade III; or glioblastoma, WHO grade IV)

          -  Supratentorial localization

          -  No more than two chemotherapy regimens including radiochemotherapy since primary
             diagnosis

          -  Eligible for either TMZ or PCV treatment

          -  Recovery from acute toxicity caused by any previous therapy

          -  Adequate organ functions

          -  KPS at least 70%

        Exclusion Criteria:

          -  Tumor surgery within 2 weeks prior to study entry

          -  Radiation therapy within 8 weeks prior to study entry

          -  Chemotherapy within 4 weeks prior to study entry (nitrosureas: 6 weeks)

          -  No more than 3 mg/day dexamethasone (or equivalent) at baseline

          -  Prior TGF-beta targeted therapy or tumor vaccination

          -  Baseline MRI shows mass effect

          -  Known active infection with HIV, HBV, or HCV; acute viral, bacterial, or fungal
             infection

          -  Significant psychiatric disorders/legal incapacity or a limited legal capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Bogdahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Regensburg, Dept. of Neurology, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck; Abteilung für Neurochirurgie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landes-Nervenklinik Wagner-Jauregg</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Franz Josef Spital, Abteilung für Neurologie</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarajishvili Institute of Clinical Neurology and Neurosurgery</name>
      <address>
        <city>Tbilisi</city>
        <zip>0114</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen, Neurochirurgische Universitätsklinik</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Kiel, Klinik für Neurochirurgie</name>
      <address>
        <city>Kiel</city>
        <zip>24106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Magdeburg, Klinik für Neurochirurgie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken Mainz, Neurochirurgische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum und Poliklinik für Neurologie, Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Saarbrücken, Neurochirurgie</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Amrita Institute of Medical Sciences &amp; Research Centre</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sree Chitra Tirunal Institute for Medical Sciences &amp; Technology, Department of Neurosurgery</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manipal Hospital; Manipal Institute for Neurological Disorders</name>
      <address>
        <city>Bangalore</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, National Institute of Mental Health and Neurosciences</name>
      <address>
        <city>Bangalore</city>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, LTMG Hospital &amp; LTM Medical College</name>
      <address>
        <city>Mumbai</city>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Neurosciences Center</name>
      <address>
        <city>New Dehli</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurological Sciences, Christian Medical College &amp; Hospital</name>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center, Neurosurgery Department</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center, Neurosurgery Department</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Neurosurgery Department</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Oncological Clinic</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital of Ministry of Health of Tatarstan Republic</name>
      <address>
        <city>Kazan</city>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burdenko Neurosurgery Research Institute</name>
      <address>
        <city>Moscow</city>
        <zip>125047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omsk State Medical Academy; State Educational Institution of Higher Professional Education</name>
      <address>
        <city>Omsk</city>
        <zip>644099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare, Samara Regional Clinical Hospital in the name of M.I. Kalinin</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polenov Neurosurgery Research Institute</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy named after I.S.M. Kirov, Neurosurgery Department</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194175</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;XXI century&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tcheliabinsk Regional Clinical Hospital; State Medical Institution for Prophylaxis and Treatment</name>
      <address>
        <city>Tcheliabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2007</study_first_submitted>
  <study_first_submitted_qc>February 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2007</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <name_title>Hubert Heinrichs, MD, PhD, Chief Medical Officer</name_title>
    <organization>Antisense Pharma</organization>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Anaplastic astrocytoma</keyword>
  <keyword>Antisense</keyword>
  <keyword>Cancer</keyword>
  <keyword>Transforming growth factor beta2 (TGF-beta2)</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Central nervous system (CNS)</keyword>
  <keyword>Convection-enhanced delivery (CED) / microperfusion</keyword>
  <keyword>Locoregional application</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Trabedersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

